Th2-polarised PrP-specific transgenic T-cells confer partial protection against murine scrapie.

Several hurdles must be overcome in order to achieve efficient and safe immunotherapy against conformational neurodegenerative diseases. In prion diseases, the main difficulty is that the prion protein is tolerated as a self protein, which prevents powerful immune responses. Passive antibody therapy...

Full description

Bibliographic Details
Main Authors: Saci Iken, Véronique Bachy, Pauline Gourdain, Annick Lim, Sylvie Grégoire, Thomas Chaigneau, Pierre Aucouturier, Claude Carnaud
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2011-09-01
Series:PLoS Pathogens
Online Access:http://europepmc.org/articles/PMC3164648?pdf=render
id doaj-ca32df08f9c447578cb0a726c547035d
record_format Article
spelling doaj-ca32df08f9c447578cb0a726c547035d2020-11-25T01:58:25ZengPublic Library of Science (PLoS)PLoS Pathogens1553-73661553-73742011-09-0179e100221610.1371/journal.ppat.1002216Th2-polarised PrP-specific transgenic T-cells confer partial protection against murine scrapie.Saci IkenVéronique BachyPauline GourdainAnnick LimSylvie GrégoireThomas ChaigneauPierre AucouturierClaude CarnaudSeveral hurdles must be overcome in order to achieve efficient and safe immunotherapy against conformational neurodegenerative diseases. In prion diseases, the main difficulty is that the prion protein is tolerated as a self protein, which prevents powerful immune responses. Passive antibody therapy is effective only during early, asymptomatic disease, well before diagnosis is made. If efficient immunotherapy of prion diseases is to be achieved, it is crucial to understand precisely how immune tolerance against the prion protein can be overcome and which effector pathways may delay disease progression. To this end, we generated a transgenic mouse that expresses the ß-chain of a T cell receptor recognizing a PrP epitope presented by the class II major histocompatibility complex. The fact that the constraint is applied to only one TCR chain allows adaptation of the other chain according to the presence or absence of tolerogenic PrP. We first show that transgene-bearing T cells, pairing with rearranged α-chains conferring anti-PrP specificity, are systematically eliminated during ontogeny in PrP+ mice, suggesting that precursors with good functional avidity are rare in a normal individual. Second, we show that transgene-bearing T cells with anti-PrP specificity are not suppressed when transferred into PrP+ recipients and proliferate more extensively in a prion-infected host. Finally, such T cells provide protection through a cell-mediated pathway involving IL-4 production. These findings support the idea that cell-mediated immunity in neurodegenerative conditions may not be necessarily detrimental and may even contribute, when properly controlled, to the resolution of pathological processes.http://europepmc.org/articles/PMC3164648?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Saci Iken
Véronique Bachy
Pauline Gourdain
Annick Lim
Sylvie Grégoire
Thomas Chaigneau
Pierre Aucouturier
Claude Carnaud
spellingShingle Saci Iken
Véronique Bachy
Pauline Gourdain
Annick Lim
Sylvie Grégoire
Thomas Chaigneau
Pierre Aucouturier
Claude Carnaud
Th2-polarised PrP-specific transgenic T-cells confer partial protection against murine scrapie.
PLoS Pathogens
author_facet Saci Iken
Véronique Bachy
Pauline Gourdain
Annick Lim
Sylvie Grégoire
Thomas Chaigneau
Pierre Aucouturier
Claude Carnaud
author_sort Saci Iken
title Th2-polarised PrP-specific transgenic T-cells confer partial protection against murine scrapie.
title_short Th2-polarised PrP-specific transgenic T-cells confer partial protection against murine scrapie.
title_full Th2-polarised PrP-specific transgenic T-cells confer partial protection against murine scrapie.
title_fullStr Th2-polarised PrP-specific transgenic T-cells confer partial protection against murine scrapie.
title_full_unstemmed Th2-polarised PrP-specific transgenic T-cells confer partial protection against murine scrapie.
title_sort th2-polarised prp-specific transgenic t-cells confer partial protection against murine scrapie.
publisher Public Library of Science (PLoS)
series PLoS Pathogens
issn 1553-7366
1553-7374
publishDate 2011-09-01
description Several hurdles must be overcome in order to achieve efficient and safe immunotherapy against conformational neurodegenerative diseases. In prion diseases, the main difficulty is that the prion protein is tolerated as a self protein, which prevents powerful immune responses. Passive antibody therapy is effective only during early, asymptomatic disease, well before diagnosis is made. If efficient immunotherapy of prion diseases is to be achieved, it is crucial to understand precisely how immune tolerance against the prion protein can be overcome and which effector pathways may delay disease progression. To this end, we generated a transgenic mouse that expresses the ß-chain of a T cell receptor recognizing a PrP epitope presented by the class II major histocompatibility complex. The fact that the constraint is applied to only one TCR chain allows adaptation of the other chain according to the presence or absence of tolerogenic PrP. We first show that transgene-bearing T cells, pairing with rearranged α-chains conferring anti-PrP specificity, are systematically eliminated during ontogeny in PrP+ mice, suggesting that precursors with good functional avidity are rare in a normal individual. Second, we show that transgene-bearing T cells with anti-PrP specificity are not suppressed when transferred into PrP+ recipients and proliferate more extensively in a prion-infected host. Finally, such T cells provide protection through a cell-mediated pathway involving IL-4 production. These findings support the idea that cell-mediated immunity in neurodegenerative conditions may not be necessarily detrimental and may even contribute, when properly controlled, to the resolution of pathological processes.
url http://europepmc.org/articles/PMC3164648?pdf=render
work_keys_str_mv AT saciiken th2polarisedprpspecifictransgenictcellsconferpartialprotectionagainstmurinescrapie
AT veroniquebachy th2polarisedprpspecifictransgenictcellsconferpartialprotectionagainstmurinescrapie
AT paulinegourdain th2polarisedprpspecifictransgenictcellsconferpartialprotectionagainstmurinescrapie
AT annicklim th2polarisedprpspecifictransgenictcellsconferpartialprotectionagainstmurinescrapie
AT sylviegregoire th2polarisedprpspecifictransgenictcellsconferpartialprotectionagainstmurinescrapie
AT thomaschaigneau th2polarisedprpspecifictransgenictcellsconferpartialprotectionagainstmurinescrapie
AT pierreaucouturier th2polarisedprpspecifictransgenictcellsconferpartialprotectionagainstmurinescrapie
AT claudecarnaud th2polarisedprpspecifictransgenictcellsconferpartialprotectionagainstmurinescrapie
_version_ 1724969805376651264